Stockscreener 앱 받기
36.31
3.92%
1.37
시간 외 거래:
36.31
전일 마감가:
$34.94
열려 있는:
$34.85
하루 거래량:
1.50M
Relative Volume:
1.43
시가총액:
$3.18B
수익:
$23.38M
순이익/손실:
$-155.22M
주가수익비율:
-16.58
EPS:
-2.19
순현금흐름:
$-134.36M
1주 성능:
+5.22%
1개월 성능:
+1.23%
6개월 성능:
+64.30%
1년 성능:
+41.34%
1일 변동 폭
$34.73
$36.89
1주일 범위
$32.59
$36.89
52주 변동 폭
$13.45
$37.08
Ideaya Biosciences Inc Stock (IDYA) Company Profile
명칭
Ideaya Biosciences Inc
전화
650-443-6209
주소
5000 SHORELINE CT, SUITE 300, SOUTH SAN FRANCISCO, CA
IDYA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IDYA
Ideaya Biosciences Inc
|
36.31 | 3.06B | 23.38M | -155.22M | -134.36M | -2.19 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Ideaya Biosciences Inc Stock (IDYA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-24 | 개시 | Truist | Buy |
| 2025-09-18 | 개시 | Guggenheim | Buy |
| 2025-09-04 | 개시 | Barclays | Overweight |
| 2025-09-04 | 개시 | Citizens JMP | Mkt Outperform |
| 2025-07-22 | 개시 | TD Cowen | Buy |
| 2025-07-10 | 재개 | Goldman | Neutral |
| 2025-06-26 | 개시 | Wells Fargo | Overweight |
| 2024-11-18 | 개시 | Stephens | Overweight |
| 2024-11-05 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-10-24 | 개시 | UBS | Buy |
| 2024-10-15 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-07-08 | 개시 | Mizuho | Outperform |
| 2024-03-08 | 개시 | BTIG Research | Buy |
| 2023-08-08 | 개시 | SVB Securities | Outperform |
| 2023-05-24 | 개시 | Goldman | Buy |
| 2023-04-24 | 업그레이드 | Stifel | Hold → Buy |
| 2023-03-23 | 개시 | Berenberg | Buy |
| 2023-02-28 | 개시 | RBC Capital Mkts | Outperform |
| 2022-12-28 | 개시 | CapitalOne | Overweight |
| 2022-10-27 | 개시 | Citigroup | Buy |
| 2022-08-15 | 다운그레이드 | Stifel | Buy → Hold |
| 2022-07-18 | 재개 | Oppenheimer | Outperform |
| 2022-03-10 | 업그레이드 | Stifel | Hold → Buy |
| 2021-09-23 | 개시 | Stifel | Hold |
| 2021-06-04 | 재개 | Robert W. Baird | Outperform |
| 2021-03-11 | 개시 | Guggenheim | Buy |
| 2020-10-07 | 개시 | Wedbush | Outperform |
| 2020-09-01 | 개시 | Northland Capital | Outperform |
| 2020-07-13 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2020-06-17 | 재확인 | H.C. Wainwright | Buy |
| 2020-04-06 | 개시 | H.C. Wainwright | Buy |
| 2020-03-13 | 개시 | ROTH Capital | Buy |
| 2019-10-17 | 개시 | Oppenheimer | Outperform |
| 2019-09-10 | 개시 | Robert W. Baird | Outperform |
| 2019-06-17 | 개시 | Citigroup | Buy |
| 2019-06-17 | 개시 | JP Morgan | Neutral |
| 2019-06-17 | 개시 | Jefferies | Buy |
모두보기
Ideaya Biosciences Inc 주식(IDYA)의 최신 뉴스
Truist Securities raises Ideaya Biosciences stock price target to $60 By Investing.com - Investing.com Canada
IDEAYA Biosciences Announces Participation at the 44th Annual J.P. Morgan Healthcare Conference | IDYA Stock News - Longbridge
IDEAYA Biosciences Announces Participation at the 44th Annual J.P. Morgan Healthcare Conference - PR Newswire
IDEAYA Biosciences Completes Targeted Full Enrollment in Randomized Pivotal Phase 2/3 Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA*A2-Negative Metastatic Uveal Melanoma - Quantisnow
Buyback Watch: Can IDEAYA Biosciences Inc 30J stock ride next bull market cycleJuly 2025 Movers & AI Powered Trade Plan Recommendations - moha.gov.vn
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
IDEAYA Biosciences (NASDAQ:IDYA) Nasdaq 100 Index Research-Driven Model - Kalkine Media
Avoiding Lag: Real-Time Signals in (IDYA) Movement - Stock Traders Daily
IDEAYA Biosciences Sees Unusually Large Options Volume (NASDAQ:IDYA) - MarketBeat
Will IDEAYA Biosciences Inc. stock benefit from commodity pricesCandlestick Trading Patterns & Next-Level Stock Intelligence, Now Free - bollywoodhelpline.com
IDEAYA Biosciences Earnings Notes - Trefis
Squarepoint Ops LLC Sells 51,937 Shares of IDEAYA Biosciences, Inc. $IDYA - MarketBeat
Biotech Stocks Shine After Hours: Novo Nordisk, IDEAYA, Healthcare Triangle Among Gainers - Nasdaq
Will IDEAYA Biosciences Inc. stock rally after Fed decisions2025 Trade Ideas & Free Expert Verified Stock Movement Alerts - Улправда
Technical Reactions to IDYA Trends in Macro Strategies - Stock Traders Daily
How IDEAYA Biosciences Inc. (30J) stock compares with tech leaders2025 Technical Patterns & Community Supported Trade Ideas - Улправда
Why IDEAYA Biosciences Inc. stock attracts high net worth investorsJuly 2025 Price Swings & Weekly High Return Stock Opportunities - Улправда
Aug EndMonth: Why IDEAYA Biosciences Inc. stock attracts high net worth investorsStock Surge & Accurate Trade Setup Notifications - Улправда
Why IDEAYA Biosciences Inc. stock appeals to dividend seekersQuarterly Profit Summary & Precise Swing Trade Alerts - Улправда
How interest rate cuts could boost IDEAYA Biosciences Inc. stockChart Signals & Consistent Return Investment Signals - Улправда
Gap Down: Will IDEAYA Biosciences Inc. stock outperform growth indexesJuly 2025 Update & Expert-Curated Trade Recommendations - Улправда
How buybacks impact IDEAYA Biosciences Inc. stock valueJuly 2025 Sentiment & Daily Profit Maximizing Tips - DonanımHaber
Why IDEAYA Biosciences Inc. (30J) stock remains top ratedPortfolio Return Summary & AI Powered Buy and Sell Recommendations - DonanımHaber
How supply shortages influence IDEAYA Biosciences Inc. (30J) stockJuly 2025 Pullbacks & Low Risk Investment Opportunities - Улправда
Aug Weekly: Why IDEAYA Biosciences Inc. stock attracts high net worth investorsTrade Signal Summary & Weekly Momentum Picks - Улправда
Will IDEAYA Biosciences Inc. stock outperform growth indexesMarket Rally & Accurate Entry/Exit Alerts - Улправда
Antibody Optimization Service Market Set to Reach USD 6.07 Billion by 2034, Growing at an 8.45% CAGR Amid Advances in Gene-Editing Technologies - GlobeNewswire Inc.
IDEAYA Biosciences (IDYA): Valuation Check After Key Darovasertib Trial Milestone and Pipeline Progress - simplywall.st
Why IDEAYA Biosciences (IDYA) Is Down 5.2% After Completing Enrollment In Pivotal Uveal Melanoma Trial - Yahoo Finance
Ideaya Biosciences to regain rights for two programs as GSK ends partnership - Investing.com Australia
Ideaya Biosciences to regain rights for two programs as GSK ends partnership By Investing.com - Investing.com South Africa
IDEAYA Biosciences (NASDAQ: IDYA) outlines GSK exit, program transfer and cash runway - Stock Titan
Redmile Group LLC Sells 102,106 Shares of IDEAYA Biosciences, Inc. $IDYA - MarketBeat
IDEAYA financials not impacted by GSK termination, says Mizuho - MSN
IDEAYA Hits Full Enrolment In Pivotal Trial Of Darovasertib For Metastatic Uveal Melanoma - RTTNews
IDEAYA Biosciences Completes Targeted Full Enrollment in Trial of Darovasertib With Pfizer's Crizotinib - marketscreener.com
IDEAYA completes enrollment for pivotal cancer drug trial - Investing.com
IDEAYA completes enrollment for pivotal cancer drug trial By Investing.com - Investing.com South Africa
IDEAYA Biosciences Completes Targeted Full Enrollment in Randomized Pivotal Phase 2/3 Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA*A2-Negative Metastatic Uveal Melanoma – Company AnnouncementFT.com - Financial Times
IDEAYA Biosciences Announces IND Submission for IDE574, a Potential First-In-Class KAT6/7 Dual Inhibitor for Breast and Lung Cancers - BioSpace
Stempoint Capital LP Purchases 98,886 Shares of IDEAYA Biosciences, Inc. $IDYA - MarketBeat
IDEAYA Biosciences submits IND for novel cancer drug IDE574 By Investing.com - Investing.com Australia
IDEAYA Biosciences submits IND for novel cancer drug IDE574 - Investing.com India
Ideaya Biosciences announces IND submission for IDE574 - marketscreener.com
Ideaya Biosciences Announces Ind Submission For Ide574 - TradingView — Track All Markets
IDEAYA Biosciences Announces IND Submission for IDE574, a Potential First-In-Class KAT6/7 Dual Inhibitor for Breast and Lung Cancers – Company Announcement - Financial Times
Hsbc Holdings PLC Has $804,000 Stake in IDEAYA Biosciences, Inc. $IDYA - MarketBeat
JPMorgan Chase & Co. Purchases 115,827 Shares of IDEAYA Biosciences, Inc. $IDYA - MarketBeat
Trading the Move, Not the Narrative: (IDYA) Edition - news.stocktradersdaily.com
Ideaya disclosed termination of GSK license agreement - MSN
GSK (GSK) Plans to End Agreement with Ideaya Biosciences - GuruFocus
Ideaya Biosciences Inc (IDYA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.52%
0.07%
자본화:
|
볼륨(24시간):